Protara Therapeutics, Inc.
TARAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. With a market capitalization of $261.3M, it sits in micro-cap territory. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Market Cap
$261.3M
Beta
1.52
P/E (TTM)
—
P/E (Fwd)
-3.03
EPS (TTM)
$-1.36
EPS (Fwd)
$-1.53
ROE
-37.3%
ROA
-24.3%
Cash
$135.8M
Total Debt
$3.1M
Free CF
-$39.3M
52W Change
40.9%
Annual Financials
Cash vs Debt
With $135.8M in cash and $3.1M in debt, TARA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$39.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -37.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Protara Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, TARA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Protara Therapeutics, Inc. and its sector.